CC Bio Win LifeArc prize after being identified as the ‘most progressed’ venture at Accelerate@Babraham - 28/2/20
CC Bio, developer of preventative solutions for microbiome dysbiosis, announced today that it has been awarded “Most Progressed Venture” from the Accelerate@Babraham 2019-2020 programme.
The £10,000 prize, supported by LifeArc and shared between CC Bio and cohort member Reflection Therapeutics, represents a validation of the company’s progress by the industry-leading Babraham bioscience community. The award announcement was the culmination of an event marking the conclusion of the programme, in which Accelerate@Babraham cohort members publicly reviewed their development over their 6 month stay on the Babraham Research Campus.
"We are delighted to receive this award from LifeArc, which validates the transformative development that CC Bio has made during our stay at Babraham" commented Dr. Matthew Cummings, CEO and co-founder of CC Bio. “The laboratory facilities and resources provided by the Accelerate@Babraham programme are second to none, and we are extremely grateful for the commitment of senior figures of the Babraham campus community to our development. Taken together, this provided the structure to truly accelerate CC Bio’s growth, and it is extremely gratifying to see this progress recognised by LifeArc today. We would especially like to thank Derek Jones [CEO Babraham Research Campus], Karolina Zapadka [Head of Accelerate@Babraham] and all of those who have assisted us throughout our time at Babraham.”
Dr. David Holbrook, head of seed funds at LifeArc, said, in comments to the Cambridge Independent: “I have been incredibly impressed with the calibre of the start-ups and the progress each has made during this second StartUP@Babraham programme.”
“It was no easy task to select who we felt had taken best advantage of the totality of the capabilities of this accelerator programme and who had really made headway in translating their science – and team – towards the next inflection point.”
“Both CC Bio and Reflection Therapeutics were impossible to separate, and it is therefore my pleasure to split the award between these two young ventures. I very much look forward to following their progress and that of the remainder of the cohort as they continue to develop the science in their respective fields.”
The Accelerate@Babraham initiative is designed to support ambitious early stage life science ventures within the Babraham Research Campus, offering short-term open access laboratory and office space, facilitating interaction with the academic community at the Babraham Institute and providing access to the campus’ global network. For further information please visit here.
About CC Bio.
CC Bio harnesses the power of bacteriophage to modify the composition of a number of human microbiome environments, resolving dysbiosis before manifestation of disease. Current active therapeutic programmes include bacterial vaginosis, and additional human health applications. CC Bio continues to build out a world-class, patent-protected IP portfolio generated by its drug discovery programme. We are interested in partnerships to expedite the progress of their research programmes, and to explore new opportunities in microbiome manipulation. CC Bio are currently fundraising and seek to close their seed round in late September. For further information visit: www.ccbio.co.uk
Images are courtesy of the Cambridge Independent. A detailed write up of the event was published by the Cambridge Independent here.